Stepping down from ticagrelor after MI: benefit in under-75s, uncertainty above

Design

Prespecified secondary analysis of a randomised trial

Population

2,697 patients event-free 1 month after PCI for acute MI (321 aged ≥75)

Primary outcome

Net clinical events (CV death, MI, stroke, BARC 2/3/5 bleeding) at 1 year

Effect

<75: 4.1% vs 7.2% (HR 0.54, 0.38 to 0.77); ≥75: 6.4% vs 11.6% (HR 0.54, 0.25 to 1.17)

A prespecified secondary analysis of the TALOS-AMI trial, published in Annals of Medicine on 30 September, examined 2,697 patients who were event-free one month after PCI for myocardial infarction and were randomised to switch from aspirin–ticagrelor to aspirin–clopidogrel or to continue.

In patients under 75, de-escalation reduced the combined endpoint of cardiovascular events and bleeding (4.1% vs 7.2%; HR 0.54) and bleeding alone. In the 321 patients aged 75 or over, event rates were numerically lower with de-escalation (6.4% vs 11.6%) but the difference was not significant, and there was no statistical evidence that the effect differed by age. Most bleeding in older patients occurred in the first six months.

Older adults bleed more on potent antiplatelet therapy, so de-escalation is attractive, but this trial was not large enough to answer the question for them on its own.

• Review potent antiplatelet therapy in older adults one month after an uncomplicated MI.
• Weigh bleeding risk carefully; most bleeds in over-75s occurred in the first six months.
• Discuss de-escalation with the cardiology team rather than switching unilaterally.
• Recheck the medication list for other bleeding risks, such as NSAIDs and anticoagulants.

Why it matters

Older adults are the group most exposed to antiplatelet bleeding, yet least represented in the trials.

Don't overread it

A subgroup analysis with only 321 older patients; it cannot confirm benefit in over-75s.

The statistics, in plain English

In the over-75s, the hazard ratio of 0.54 was the same as in younger patients, but the interval (0.25 to 1.17) crosses 1 because numbers were small. A non-significant interaction test means no evidence that age changes the effect — not proof that it does not.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.